Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Black Diamond Therapeutics, Inc.BDTX · Entity 6669 | SEE REMARKS | January 21, 2026 | January 23, 2026 |
| Radius Health, Inc.RDUS · Entity 124173 | Sr. VP, General Counsel | February 22, 2019 | February 26, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Black Diamond Therapeutics, Inc.
Report date January 21, 2026 · Filed January 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.57 · Expires 2036-01-20 | Direct | 250,000 |
Reported balance
After 2026-01-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-21 · Grant · Acquired 250,000 · Balance 250,000 F1: 25% of the shares subject to this option shall vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to this option shall vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Radius Health, Inc.
Report date February 22, 2019 · Filed February 26, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,944 |
Reported balance
After 2019-02-22 transaction · row 1
1 source rowRow 1 · 2019-02-22 · Grant · Acquired 15,000 · Balance 17,944 F1: The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. The restricted stock units vest in four substantially equal annual installments on each of the first four anniversaries of the grant date of February 22, 2019, subject to continued service with RDUS through such dates. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.18 · Expires 2029-02-22 | Direct | 55,000 |
Reported balance
After 2019-02-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-02-22 · Grant · Acquired 55,000 · Balance 55,000 F2: 25% of the shares subject to the stock option shall vest on February 22, 2020, and the remaining shares shall vest in substantially equal monthly installments over the following three years, subject to continued service with RDUS through such dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. The restricted stock units vest in four substantially equal annual installments on each of the first four anniversaries of the grant date of February 22, 2019, subject to continued service with RDUS through such dates.
F2: 25% of the shares subject to the stock option shall vest on February 22, 2020, and the remaining shares shall vest in substantially equal monthly installments over the following three years, subject to continued service with RDUS through such dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 14, 2020 Filed Sep 16, 2020 22:11 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionCommon Stock | 4,078 | $3.20 | $13,049.60 |
DisclosureSEC source: 0000899243-20-025361 · doc4.xml · nonDerivative · entry 1 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,078 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:55 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | PurchaseCommon Stock | 3,000 | $19.00 | $57,000.00 |
DisclosureSEC source: 0000899243-20-003354 · doc4.xml · nonDerivative · entry 1 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · shares: On February 3, 2020, Reporting Person purchased 3,000 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:50 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 78,751 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-20-002440 · doc4.xml · derivative · entry 1 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,751 Underlying: Common Stock · 78,751 shares Expires 2030-01-29 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 3, 2021, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 18:14 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $19.18 | $0.00 |
DisclosureSEC source: 0001209191-19-013706 · doc4.xml · derivative · entry 2 Hatzis-Schoch Brent · CIK 0001637054 · Sr. VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2029-02-22 F2 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on February 22, 2020, and the remaining shares shall vest in substantially equal monthly installments over the following three years, subject to continued service with RDUS through such dates. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 18:14 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantCommon Stock | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-013706 · doc4.xml · nonDerivative · entry 1 Hatzis-Schoch Brent · CIK 0001637054 · Sr. VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,944 F1 · price: The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. The restricted stock units vest in four substantially equal annual installments on each of the first four anniversaries of the grant date of February 22, 2019, subject to continued service with RDUS through such dates. Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 19:42 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $37.83 | $0.00 |
DisclosureSEC source: 0001209191-18-010551 · doc4.xml · derivative · entry 1 Hatzis-Schoch Brent · CIK 0001637054 · Sr. VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2028-02-12 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on February 13, 2019 and the remaining shares shall vest in substantially equal monthly installments over the following three years. Read SEC document |
| November 10, 2017 Filed Nov 13, 2017 07:26 UTC | Radius Health, Inc. RDUS · Entity 124173 | PurchaseCommon Stock | 1,778 | $28.09 | $49,942.78 |
DisclosureSEC source: 0001209191-17-060138 · doc4.xml · nonDerivative · entry 1 Hatzis-Schoch Brent · CIK 0001637054 · Sr. VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,278 Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 16:27 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $45.65 | $0.00 |
DisclosureSEC source: 0001209191-17-013260 · doc4.xml · derivative · entry 1 Hatzis-Schoch Brent · CIK 0001637054 · Sr. VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2027-02-16 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on February 17, 2018 and the remaining shares shall vest in substantially equal monthly installments over the following three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.